Pure Encapsulations | Probiotic 50B
Probiotic 50B 60's is acid-resistant capsules with pH targeted release; High-potency probiotic support for healthy intestinal microflora
Don't miss out on exclusive discounts and free shipping – they're just a few clicks away!
Primary Benefits
Supports healthy intestinal microflora to promote digestive and immune health‡
High-potency probiotic provides 50 billion CFU of a combination of beneficial bacteria
Offered in acid-resistant capsules with pH targeted release to deliver maximal viable organisms to the digestive tract
Dietary Considerations
Dairy/ Milk Free
Gluten Free
Soy Free
Non-GMO
Product Details
Acid-resistant capsules with pH targeted release; high-potency probiotic support for healthy intestinal microflora
Probiotic 50B provides 50 billion CFU of the beneficial bacteria Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum and Bifidobacterium lactis in acid-resistant capsules with pH targeted release to deliver maximal viable organisms to the digestive tract. These five researched strains promote healthy intestinal ecology to support gastrointestinal and immune health. Clinical studies indicate that lactobacilli and bifidobacteria supplementation supports intestinal epithelial integrity and healthy immune response.
Probiotic 50B provides a 50 billion CFU per capsule blend of lactobacilli and bifidobacteria to promote digestive and immune health.
Suggested Use
As a dietary supplement, take 1 capsule daily, with or between meals.
Warnings
Probiotics may be contraindicated for immunocompromised individuals. If you are pregnant or lactating, have any health condition or are immunocompromised, or are taking any medication, consult your health professional before use.
Keep out of the reach of children.
Use only if safety seal is intact. Keep refrigerated.
Natural color variations may occur.
Heat Sensitive:Overnight shipping is recommended. Not recommended for international shipping.
References:
Gut permeability and food allergies—PubMed. (n.d.). Retrieved November 3, 2024, from https://pubmed.ncbi.nlm.nih.gov/21070397/
Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children—Updated analysis of randomised controlled trials—PubMed. (n.d.). Retrieved November 3, 2024, from https://pubmed.ncbi.nlm.nih.gov/23841880/
Pace, F., Pace, M., & Quartarone, G. (2015). Probiotics in digestive diseases: Focus on Lactobacillus GG. Minerva Gastroenterologica E Dietologica, 61(4), 273–292.
Paineau, D., Carcano, D., Leyer, G., Darquy, S., Alyanakian, M.-A., Simoneau, G., Bergmann, J.-F., Brassart, D., Bornet, F., & Ouwehand, A. C. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: A double-blind, randomized, controlled trial. FEMS Immunology and Medical Microbiology, 53(1), 107–113. https://doi.org/10.1111/j.1574-695X.2008.00413.x
Prevention of travellers’ diarrhoea by Lactobacillus GG - PubMed. (n.d.). Retrieved November 3, 2024, from https://pubmed.ncbi.nlm.nih.gov/2184847/
Probiotic bacteria down‐regulate the milk‐induced inflammatory response in milk‐hypersensitive subjects but have an immunostimulatory effect in healthy subjects—Pelto—1998—Clinical & Experimental Allergy—Wiley Online Library. (n.d.). Retrieved November 3, 2024, from https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2222.1998.00449.x
Sindhu, K. N. C., Sowmyanarayanan, T. V., Paul, A., Babji, S., Ajjampur, S. S. R., Priyadarshini, S., Sarkar, R., Balasubramanian, K. A., Wanke, C. A., Ward, H. D., & Kang, G. (2014). Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: A randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 58(8), 1107–1115. https://doi.org/10.1093/cid/ciu065
Szajewska, H., Skórka, A., Ruszczyński, M., & Gieruszczak-Białek, D. (2007). Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Alimentary Pharmacology & Therapeutics, 25(8), 871–881. https://doi.org/10.1111/j.1365-2036.2007.03282.x